Back to search
Myasthenia Gravis Crisis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Myasthenia Gravis Crisis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Myasthenia Gravis Crisis trials you may qualify forMyasthenia Gravis (MG) is a rare autoimmune disease that causes muscle weakness and fatigue. It occurs when the immune system produces antibodies that block com…
This study plans to learn more about if the drug efgartigimod can be used in the hospital to treat exacerbations in participants with myasthenia gravis (MG). Ef…
The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it…
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among differe…
This study is a multicenter, prospective, observational research. It will register the basic demographic information, medical history characteristics, clinical…
This study compares the clinical effectiveness of Intravenous Immunoglobulin (IVIG) versus Plasma Exchange (PLEX) in patients experiencing a myasthenic crisis.…
Efgartigimod in Myasthenic Crisis Background Myasthenia gravis (MG) is a prevalent autoimmune disorder affecting neuromuscular junctions, characterized by weakn…
The average annual incidence of Myasthenia gravis is up to (8.0-20.0) / 100,000 people. Myasthenia gravis is an acquired autoimmune disease. All skeletal muscle…